congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
I-DXd
SITC 2024 | November 6-10, 2024
Evaluation of immunomodulatory effects of ifinatamab deruxtecan (I-DXd) in the IDeate-PanTumor01 phase 1/2 study in patients with advanced solid tumors